

## QUALIFICATION CERTIFICATE

I, Christopher Moreau, Chief Executive Officer of Algernon Pharmaceuticals Inc. (the “**Issuer**”), hereby certify that:

- (a) the Issuer is entitled to file a base shelf short form prospectus under National Instrument 44-101 and National Instrument 44-102 (together, the “**Instruments**”) in each of the provinces of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland & Labrador by virtue of the Issuer satisfying the requirements of Section 2.2 of the Instruments; and
- (b) all of the material incorporated by reference in the preliminary base shelf short form prospectus and not previously filed is being filed with the preliminary base shelf short form prospectus.

DATED: February 4, 2021

**ALGERNON PHARMACEUTICALS INC.**

*“Christopher Moreau”*

---

Christopher Moreau  
Chief Executive Officer